News & Analysis on Clinical Trial Services & Contract Research And Development
China and India are forecasted as the most exciting prospects for European pharmaceutical and biotechnology companies. Despite having over a third of the world's population, Asia accounts for only one fifth of global pharmaceutical drug consumption.
GlaxoSmithKline has become the latest drugmaker to fall foul of regulatory authorities for failing to meet manufacturing standards.
Metabolex has announced positive clinical trial results for its oral insulin sensitiser for type 2 diabetes, which is primarily designed to eliminate the dose-limiting side effects of the currently marketed sensitisers.
GE Healthcare announced the launch of two new purification tools designed to meet growing industry needs for the advancement of monoclonal antibody (MAbs) research and development. The tools become the latest offering in the chromatography media...
Singapore's pharmaceutical output is likely to be flat this year, a casualty of increasing pressure from generic drug firms. The prediction, made by a Singapore official comes after the country experienced a 40 per cent growth in the biomedical sector...
US pharmaceutical giant Pfizer and French drugmaker Sanofi-Aventis have filed with the US Food and Drug Administration seeking marketing approval for Exubera, an inhaled human insulin powder, for the treatment of diabetes.
Although US biotechnology company, Chiron, fully intends to be able to provide its Fluvirin flu vaccine for the 2005/6 flu season, it says it is difficult to predict the number of doses it will be able to produce.
The emergence of nanotechnology is likely to have a significant impact on drug delivery sector, affecting just about every route of administration from oral to injectable, according to specialist market research firm NanoMarkets.
US researchers have discovered that cholesterol plays a key role in anchoring a signalling pathway, which has been linked to cell division and cancer. The findings could identify cholesterol as an unlikely drug target.
There is no doubt that the introduction of stents, and latterly those that deliver pharmacological agents, has revolutionised the treatment of coronary artery disease over the last 10 years and all but consigned heart surgery to second-line use. But...